Definitive Chemoradiotherapy with the Addition of Lapatinib in Inoperable, Locally Advanced Oesophageal and OGJ Adenocarcinoma A Phase I study
Latest Information Update: 18 Jul 2023
At a glance
- Drugs Lapatinib (Primary)
- Indications Oesophageal cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 17 Oct 2013 New trial record